- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01863784
A Study to Evaluate the Pharmacokinetics of JNJ-38518168 in Patients With Mild and Moderate Hepatic Impairment Compared With Patients With Normal Hepatic Function
May 10, 2016 updated by: Janssen Research & Development, LLC
An Open-Label Study to Evaluate the Pharmacokinetics of Multiple Oral Doses of 30 mg JNJ-38518168 in Subjects With Mild and Moderate Hepatic Impairment Compared With Subjects With Normal Hepatic Function
The purpose of this study is to characterize the pharmacokinetics (what the body does to the study medication) of JNJ-38518168 at approximately steady-state (stable medication levels) after administration of multiple oral 30 mg doses of JNJ-38518168 to participants with mild or moderate hepatic (liver) impairment (abnormal function) compared with participants with normal hepatic function.
Study Overview
Detailed Description
This is an open-label (both [participants and investigator] know what treatment participants will receive) and multicenter study.
The study consists of 3 phases: a screening phase (approximately 3 weeks), a treatment phase (from day -2 [2 days before the administration of study medication] to Day 18), and an end-of-study phase (7 to 10 days after the last dose of study medication).
Approximately 24 participants (participants with mild hepatic impairment, moderate hepatic impairment, and normal liver function) will receive JNJ-38518168 for 14 days.
Hepatic impairment will be evaluated according to Child-Pugh score.
It consists of 5 clinical measures (amount of ascites [an abnormal accumulation of fluid in the abdomen], total bilirubin [mg/dL], albumin [g/dL], international normalized ratio, and degree of encephalopathy [abnormal functioning of the brain]).
Each is scored from 0 (less severity) to 3 (highest severity).
Total Child-Pugh score is the sum of all subscores and is graded as: mild (5-6 points), moderate (7-9 points), and severe (10-15 points).
Safety will be evaluated by the assessment of adverse events, clinical laboratory tests, vital signs, body weight, physical examination, and 12-lead electrocardiogram which will be monitored at various timepoints throughout the study.
The total duration of study participation for each participant is approximately 6 weeks.
Study Type
Interventional
Enrollment (Actual)
28
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Florida
-
Orlando, Florida, United States
-
-
Tennessee
-
Knoxville, Tennessee, United States
-
-
Texas
-
San Antonio, Texas, United States
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Have normal liver function for the normal hepatic function group
- Have mild or moderate liver diseases as defined by the Child-Pugh Classification and be clinically stable overall for the mild or moderate liver disease groups
- Doses of drugs used to treat other illnesses or conditions related to liver disease must be stable for at least 4 weeks before the first dose of study medication with the exception of thyroid replacement hormone, in which case the dose must be stable for 3 months before the first dose of study medication. Doses of these drugs must also be stable during the course of the study
- If an illness with a fever occurs within one week of the start of dosing, dosing must be postponed until the body temperature is normal for at least 72 hours
- Participants must agree to use one of the contraception methods defined in the protocol
Exclusion criteria:
- Hepatic insufficiency secondary to autoimmune hepatitis or obstructive liver disease
- Allergy to heparin or history of heparin-induced thrombocytopenia
- All participants must have a negative human immunodeficiency virus test. Participants with normal liver function must test negative for hepatitis B and hepatitis C
- Severe ascites (an abnormal accumulation of fluid in the abdomen) or severe pleural effusion (fluid around the lungs)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: JNJ-38518168
|
All participants will receive JNJ-38518168 30 mg tablet once daily from Day 1 to Day 14.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Maximum observed plasma concentration of JNJ-38518168 at approximately steady-state after multiple doses
Time Frame: Day 14 (predose, postdose [1, 2, 3, 4, 5, 6, 7, 8, 12, 24, 48, 72, and 96 hours])
|
Day 14 (predose, postdose [1, 2, 3, 4, 5, 6, 7, 8, 12, 24, 48, 72, and 96 hours])
|
Area under the plasma concentration-time curve of JNJ-38518168 at approximately steady-state after multiple doses
Time Frame: Day 14 (predose, postdose [1, 2, 3, 4, 5, 6, 7, 8, 12, 24, 48, 72, and 96 hours])
|
Day 14 (predose, postdose [1, 2, 3, 4, 5, 6, 7, 8, 12, 24, 48, 72, and 96 hours])
|
Time to reach the maximum observed plasma of JNJ-38518168 at approximately steady-state after multiple doses
Time Frame: Day 14 (predose, postdose [1, 2, 3, 4, 5, 6, 7, 8, 12, 24, 48, 72, and 96 hours])
|
Day 14 (predose, postdose [1, 2, 3, 4, 5, 6, 7, 8, 12, 24, 48, 72, and 96 hours])
|
Apparent clearance of JNJ-38518168 at approximately steady-state after multiple doses
Time Frame: Day 14 (predose, postdose [1, 2, 3, 4, 5, 6, 7, 8, 12, 24, 48, 72, and 96 hours])
|
Day 14 (predose, postdose [1, 2, 3, 4, 5, 6, 7, 8, 12, 24, 48, 72, and 96 hours])
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Maximum observed plasma concentration of JNJ-38518168 after single dose
Time Frame: Day 1 (predose, postdose [1, 2, 3, 4, 5, 6, 7, 8, 12, and 24 hours])
|
Day 1 (predose, postdose [1, 2, 3, 4, 5, 6, 7, 8, 12, and 24 hours])
|
Area under the plasma concentration-time curve of JNJ-38518168 after single dose
Time Frame: Day 1 (predose, postdose [1, 2, 3, 4, 5, 6, 7, 8, 12, and 24 hours])
|
Day 1 (predose, postdose [1, 2, 3, 4, 5, 6, 7, 8, 12, and 24 hours])
|
Time to reach the maximum observed plasma of JNJ-38518168 after single dose
Time Frame: Day 1 (predose, postdose [1, 2, 3, 4, 5, 6, 7, 8, 12, and 24 hours])
|
Day 1 (predose, postdose [1, 2, 3, 4, 5, 6, 7, 8, 12, and 24 hours])
|
Urine concentration-time data of JNJ-38518168 after single dose
Time Frame: Day 1 (predose, postdose [1, 2, 3, 4, 5, 6, 7, 8, 12, and 24 hours])
|
Day 1 (predose, postdose [1, 2, 3, 4, 5, 6, 7, 8, 12, and 24 hours])
|
Plasma protein binding of JNJ-38518168
Time Frame: Day 1 (postdose [4 hours]) and Day 14 (predose, postdose [4 hours])
|
Day 1 (postdose [4 hours]) and Day 14 (predose, postdose [4 hours])
|
Number of participants with adverse events
Time Frame: Up to 6 weeks
|
Up to 6 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2013
Primary Completion (Actual)
November 1, 2013
Study Completion (Actual)
November 1, 2013
Study Registration Dates
First Submitted
May 23, 2013
First Submitted That Met QC Criteria
May 23, 2013
First Posted (Estimate)
May 29, 2013
Study Record Updates
Last Update Posted (Estimate)
May 12, 2016
Last Update Submitted That Met QC Criteria
May 10, 2016
Last Verified
May 1, 2016
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CR101336
- 38518168ARA1005 (Other Identifier: Janssen Research & Development, LLC)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hepatic Impairment
-
PfizerRecruitingHealthy Volunteers | Moderate Hepatic Impairment | Severe Hepatic ImpairmentUnited States
-
GlycoMimetics IncorporatedCompletedModerate Hepatic Impairment | Normal Hepatic FunctionUnited States
-
Astellas Pharma Europe B.V.Medivation, Inc.CompletedSevere Hepatic Impairment | Normal Hepatic FunctionBulgaria
-
Agios Pharmaceuticals, Inc.CompletedModerate Hepatic ImpairmentUnited States
-
Merck Sharp & Dohme LLCCompletedModerate Hepatic ImpairmentUnited States
-
EQRx International, Inc.CompletedSevere Hepatic ImpairmentUnited States
-
PfizerCompleted
-
TakedaCompletedSevere Hepatic ImpairmentUnited States
-
Merck Sharp & Dohme LLCNot yet recruitingHepatic Impairment (HI)
-
Bausch Health Americas, Inc.TerminatedSevere Hepatic ImpairmentUnited States
Clinical Trials on JNJ-38518168
-
Janssen Research & Development, LLCCompletedAsthmaUnited States, France, United Kingdom, Germany, Israel, Canada
-
Janssen Research & Development, LLCCompleted
-
Janssen Research & Development, LLCCompleted
-
Janssen Research & Development, LLCCompleted
-
Johnson & Johnson Pharmaceutical Research & Development...TerminatedRheumatoid ArthritisPoland, United Kingdom, Taiwan, Spain, Korea, Republic of, Belgium, Russian Federation, Czech Republic, Netherlands, Ireland
-
Janssen Research & Development, LLCTerminatedRheumatoid ArthritisPoland, Ukraine, Taiwan, United States, Colombia, Mexico, Japan, Korea, Republic of, Russian Federation, Argentina, Chile, Thailand, Hungary, Romania, Czechia, Latvia
-
Janssen Research & Development, LLCCompletedHealthyUnited States
-
Johnson & Johnson Pharmaceutical Research & Development...CompletedRheumatoid ArthritisUnited States
-
Janssen Research & Development, LLCCompleted
-
Janssen Research & Development, LLCCompleted